Sticking to sugars at the metastatic site: Sialyltransferase ST6GalNAc2 acts as a breast cancer metastasis suppressor

Cancer Discovery

Volumn 4, Issue 3, 2014, Pages 275-277

  Ferrer, Christina M ^a   Reginato, Mauricio J ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOHYDRATE ANTIGEN; ESTROGEN RECEPTOR; GALECTIN 3; GCS 100; GLYCAN DERIVATIVE; LECTIN; SIALIC ACID; UNCLASSIFIED DRUG;

ALPHA N ACETYLGALACTOSAMINIDE ALPHA 2,6 SIALYTRANSFERASE1 GENE; ARTICLE; BREAST METASTASIS; CELL ADHESION; CELL INVASION; CELL SURVIVAL; DISEASE COURSE; DOWN REGULATION; ENDOTHELIUM CELL; GLYCOSYLATION; HUMAN; MASS SPECTROMETRY; NONHUMAN; PROTEIN BINDING; RNA INTERFERENCE; TUMOR SUPPRESSOR GENE;

ANIMALS; BREAST NEOPLASMS; FEMALE; GALECTIN 3; HUMANS; LUNG NEOPLASMS; SIALYLTRANSFERASES;

EID: 84895808222     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-14-0075     Document Type: Article

References (10)

1. Cazet A, Julien S, Bobowski M, Burchell J, Delannoy P. Tumour-associated carbohydrate antigens in breast cancer. Breast Cancer Res 2010;12:204.
2. Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, Nguyen DX, et al. Genes that mediate breast cancer metastasis to the brain. Nature 2009;459:1005-1009.
3. Rabinovich GA, Toscano MA. Turning 'sweet' on immunity: galectin- glycan interactions in immune tolerance and inflammation. Nat Rev Immunol 2009;9:338-352.
4. Newlaczyl AU, Yu LG. Galectin-3-a jack-of-all-trades in cancer. Cancer Lett 2011;313:123-128.
5. Murugaesu N, Iravani M, van Weverwijk A, Ivetic A, Johnson DA, Antonopoulos A, et al. An in vivo functional screen identifi es ST6GalNAc2 sialyltransferase as a breast cancer metastasis suppressor. Cancer Discov 2014;4:304-317.
6. Gumireddy K, Li A, Gimotty PA, Klein-Szanto AJ, Showe LC, Katsaros D, et al. KLF17 is a negative regulator of epithelial-mesenchymal transition and metastasis in breast cancer. Nat Cell Biol 2009; 11: 1297-1304.
7. Chauhan D, Li G, Podar K, Hideshima T, Neri P, He D, et al. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells. Cancer Res 2005;65:8350-8358.
8. Tsuboi S, Sutoh M, Hatakeyama S, Hiraoka N, Habuchi T, Horikawa Y, et al. A novel strategy for evasion of NK cell immunity by tumours expressing core 2 O-glycans. EMBO J 2011;30:3173-3185.
9. Muller I, Jenner J, Handgretinger R, Riberdy J, Kerst G. Glycosylation and lectins-examples of immunesurveillance and immune evasion. Histol Histopathol 2004;19:527-533.
10. Demotte N, Wieers G, Van Der Smissen P, Moser M, Schmidt C, Thielemans K, et al. A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumor-infi ltrating lymphocytes and favors tumor rejection in mice. Cancer Res 2010;70:7476-7488.